A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy

NCT06172634 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Pancreas Cancer

Interventions

DRUG: dentritic cell infusion and immunecheckpoint inhibitor

Sponsor

Soonchunhyang University Hospital